Legend Biotech (LEGN) Accumulated Expenses (2019 - 2025)

Legend Biotech (LEGN) has reported Accumulated Expenses for 7 consecutive years, with $195.4 million the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses rose 17.57% year-over-year to $195.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $195.4 million (up 17.57% YoY) and the FY2025 annual result came in at $195.4 million, up 17.57% from the prior year.
• Accumulated Expenses advanced to $195.4 million in Q4 2025 per LEGN's latest filing, from $147.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for LEGN reached as high as $195.4 million in Q4 2025 and fell as low as $80096.0 in Q1 2021.
• A 5-year average of $128.1 million and a median of $141.7 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses surged 128705.84% — and 2023, when it slumped 33.57%.
• Year by year, Accumulated Expenses stood at $123.6 million in 2021, then surged by 49.01% to $184.1 million in 2022, then sank by 33.57% to $122.3 million in 2023, then soared by 35.89% to $166.2 million in 2024, then rose by 17.57% to $195.4 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $195.4 million, $147.2 million, and $138.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.